Hoelzer, D; Bassan, R; Boissel, N; Roddie, C; Ribera, JM; Jerkeman, M; ESMO Guidelines Committee; (2024) ESMO Clinical Practice Guideline interim update on the use of targeted therapy in acute lymphoblastic leukaemia. Annals of Oncology , 35 (1) pp. 15-28. 10.1016/j.annonc.2023.09.3112.

Preview

Text 1-s2.0-S0923753423040097-main.pdf - Accepted Version Download (1MB) | Preview

Abstract

The introduction of immunotherapy with monoclonal antibodies (mAbs) is a major step forward for adults and children with B-lineage acute lymphoblastic leukaemia (ALL) and will change the treatment paradigm substantially. With intensive multi-agent chemotherapy (ChT) in children with ALL, long-term cure has been achieved in ≥90% of patients; however, this approach is often associated with long-term sequelae. Until recently, aggressive ChT has also been used in adult patients, with an overall cure rate of 50%. Survival rates are higher (∼70%) in adolescents and young adults (AYAs) but lower (<20%) in elderly patients. The major hazard of treatment is myelotoxicity leading to infection, which causes death in the induction and consolidation phases in 1%-3% of children and ≤10% of adults, increasing to ≤20% of elderly patients aged >70 years. With haematopoietic stem cell transplantation (HSCT), cure can be achieved in approximately half of adults; however, this approach is also associated with substantial toxicity and treatment-related mortality (TRM) rates of 10%-20%.

Download activity - last month

Export as XMLJSONCSV

Download activity - last 12 months

Export as JSONCSVXML

Downloads by country - last 12 months

Export as JSONCSVXML

Archive Staff Only

View Item